Address: Av. del Libertador 742 – Vicente López, Buenos Aires,Argentina
Tel: +54 11 4909 8000
Web: http://www.sidus.com.ar/web/gef.nsf/?Open
Bio Sidus Argentina was created at the beginning of the 1980s, and was the first and is now the largest biotechnology company in Latin America. Specializing in Interferon EPO for many years, Bio Sidus Argentina is now looking towards the possibilities opened up by monoclonal antibodies, and has created a range of transgenic animals, which have been recognized as one of the most important biotechnological innovations in recent years.
Biopharmaceuticals
Sidus was originally established in 1938. Today, the Sidus Pharmaceutical Group is one of the most respected in Argentina and Latin America. To what extent is the company today still…
Miriam Martinez, CEO of Laboratorios Duncan and VP of CAPGEN, discusses the challenges her company faces as a generic manufacturer in a branded generic market and their plans for growth…
KPMG’s lead healthcare consultant in Argentina gives an in-depth analysis of the long-term needs and objectives driving change in the industry, the structural issues that need to be overcome before…
The founder and president of Close Up International shares the story of the genesis, evolution, and growth of both his company and the prescription auditing industry, as well as his…
The executive director of Latin America’s largest plasma fractionation plant, a publicly-funded laboratory within the 400 year old National University of Cordoba, discusses the organization’s social responsibility as a provider and leader…
Over the course of a day of unprecedented collaboration, Argentina’s biotech industry came together to discuss the challenges facing their industry in Argentina and the region at BioArgentina 2014, an event…
Nicola Carusoni, PwC’s lead pharmaceutical partner in Buenos Aires, gives an overview of the key trends in the Argentinian pharma industry and discusses the importance of PwC as a partner to the…
Mauro Bono discusses the challenges of building a company from the interior of Argentina, and shares his assessment of the key issues driving and preventing change in the country’s pharmaceutical…
Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations. How did you become part of Glenmark,…
“We are glad to host, together with ETIF, an event bringing forward pharma technologies to Argentinian patients. We hope this collaboration with ETIF will be the first of many” – Ines…
President of the company, Alberto Alvarez-Saavedra, discusses the company’s transformation into a professional organization, and the strategy which has driven remarkable growth in recent years, and will continue to do so…
On behalf of the chamber of industry that represents research-based pharma and biopharma companies in Argentina, Ernesto Felicio discusses the current challenges facing the industry, and the chambers current agenda…
Long-term strategy is the name of the game for Janssen. Alejandro Smolje, the company’s director of finance for Latin America South, outlines how that strategy is implemented in Argentina and…
See our Cookie Privacy Policy Here
